Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma

Journal of Leukocyte Biology

Volumn 84, Issue 2, 2008, Pages 561-576

  Koldehoff, Michael ^a   Beelen, Dietrich W ^a   Elmaagacli, Ahmet H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Bortezomib; Small interfering RNA; VEGF

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; PROTEASOME; SMALL INTERFERING RNA; VASCULOTROPIN;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL LINE; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENE SILENCING; GENETIC RESISTANCE; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL; MALE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANCE GENE 1; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; GENE SILENCING; GENE THERAPY; HLA ANTIGENS; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA, MESSENGER; RNA, SMALL INTERFERING; SIBLINGS; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 48649092981     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0907632     Document Type: Article

References (55)

1. Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., Kienast, J. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interaction in multiple myeloma. Blood 95, 2630-2636.
2. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., Dammacco, F. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93, 3064-3073.
3. Podar, K., Tai, Y. T., Davies, F. E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B. K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P., Anderson, K. C. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98, 428-435.
4. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., Gabrilovich, D. I. (1998) Vascular endothelial growth factor affects dendritic cell maturation though the inhibition of nuclear factor-κ B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232.
5. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., Carbone, D. P. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096-1103.
6. Podar, K., Catley, L. P., Tai, Y. T., Shringarpure, R., Carvalho, P., Hayashi, T., Burger, R., Schlossman, R. L., Richardson, P. G., Pandite, L. N., Kumar, R., Hideshima, T., Chauhan, D., Anderson, K. C. (2004) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in bone marrow microenvironment. Blood 103, 3474-3479.
7. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14.
8. Fang, S., Weissmann, A. M. (2004) A field guide to ubiquitylation. Cell. Mol. Life Sci. 61, 1546-1561.
9. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P., Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617.
10. Bross, P. F., Kane, R., Farrell, A. T., Abraham, S., Benson, K., Brower, M. E., Bradley, S., Gobburu, J. V., Goheer, A., Lee, S. L., Leighton, J., Liang, C. Y., Lostritto, R. T., McGuinn, W. D., Morse, D. E., Rahman, A., Rosario, L. A., Verbois, S. L., Williams, G., Wang, Y. C., Pazdur, R. (2004) Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10, 3954-3964.
11. Mimnaugh, E. G., Xu, W., Vos, M., Yuan, X., Isaacs, J. S., Bisht, K. S., Gius, D., Neckers, L. (2004) Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vascuolization, enhances antitumor activity. Mol. Cancer Ther. 3, 551-566.
12. Catley, L., Tai, Y. T., Chauhan, D., Anderson, K. C. (2005) Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist. Updat. 8, 205-218.
13. Gatto, S., Scappini, B., Pham, L., Onida, F., Milella, M., Ball, G., Ricci, C., Divoky, V., Verstovsek, S., Kantarjian, H. M., Keating, M. J., Cortes-Franco, J. E., Beran, M. (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistance to imatinib mesylate. Haematologica 88, 853-863.
14. Chauhan, D., Li, G., Podar, K., Hideshima, T., Shringarpure, R., Catley, L., Mitsiades, C., Munshi, N., Tai, Y. T., Suh, N., Gribble, G. W., Honda, T., Schlossman, R., Richardson, P., Sporn, M. B., Anderson, K. C. (2004) The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103, 3158-3166.
15. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811.
16. Novina, C. D., Sharp, P. A. (2004) The RNAi revolution. Nature 430, 161-164.
17. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
18. Elbashir, S. M., Lendeckel, W., Tuschl, T. (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15, 188-200.
19. Wilda, M., Fuchs, U., Wössmann, W., Borkhardt, A. (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21, 5716-5724.
20. Elmaagacli, A. H., Koldehoff, M., Peceny, R., Klein-Hitpass, L., Ottinger, H., Beelen, D. W., Opalka, B. (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90, 326-334.
21. Koldehoff, M., Steckel, N. K., Beelen, D. W., Elmaagacli, A. H. (2006) Synthetic small interfering RNAs reduce bcr-abl gene expression in leukemic cells of de novo Philadelphia(+) acute myeloid leukemia. Clin. Exp. Med. 6, 45-47.
22. Takei, Y., Kadomatsu, K., Yuzawa, Y., Matsuo, S., Muramatsu, T. (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64, 3365-3370.
23. Elmaagacli, A. H., Freist, A., Hahn, M., Opalka, B., Seeber, S., Schaefer, U. W., Beelen, D. W. (2001) Estimating the relapse in chronic myeloid leukemia patients after allogeneic stem cell transplantation by the amount of bcr-abl fusion transcripts detected using a new real-time polymerase chain reaction method. Br. J. Haematol. 113, 1072-1075.
24. Koldehoff, M., Steckel, N. K., Beelen, D. W., Elmaagacli, A. H. (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukemia. Clin. Exp. Med. 7, 47-55.
25. Chi, J. T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., Brown, P. O. (2003) Genomewide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 6343-6346.
26. Zhang, L., Yang, N., Mohamed-Hadley, A., Rubin, S. C., Coukos, G. (2003) Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 303, 1169-1178.
27. Filleur, S., Courtin, A., Ait-Si-Ali, S., Guglielmi, J., Merle, C., Harel-Bellan, A., Clézardin, P., Cabon, F. (2003) siRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63, 3919-3922.
28. Guan, H., Zhou, Z., Wang, H., Jia, S. F., Liu, W., Kleinerman, E. S. (2005) A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a Xenograft mouse model. Clin. Cancer Res. 11, 2662-2669.
29. Reich, S. J., Fosnot, J., Kuroki, A., Tang, W., Yang, X., Maguire, A. M., Bennett, J., Tolentino, M. J. (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216.
30. Hu, X., Hipolito, S., Lynn, R., Abraham, V., Ramos, S., Wong-Staal, F. (2004) Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res. 32, 4609-4617.
31. Morita, K., Yamate, K., Kurakata, S., Abe, K., Watanabe, K., Koizumi, M., Imanishi, T. (2006) Inhibition of VEGF mRNA by 2′-O,4′-C-ethylene- bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions. Nucleosides Nucleotides Nucleic Acids 25, 503-521.
32. Levine, A. M., Tulpule, A., Quinn, D. I., Gorospe III, G., Smith, D. L., Hornor, L., Boswell, W. D., Espina, B. M., Groshen, S. G., Masood, R., Gill, P. S. (2006) Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J. Clin. Oncol. 24, 1712-1719.
33. Kretschmer-Kazemi Far, R., Sczakiel, G. (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res. 31, 4417-4424.
34. Mohle, R., Rafii, S., Moore, M. A. (1998) The role of endothelium in the regulation of hematopoietic stem cell migration. Stem Cells 16, 159-165.
35. Bautz, F., Rafii, S., Kanz, L., Mohle, R. (2000) Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hematopoietic microenvironment. Exp. Hematol. 28, 700-706.
36. Le Gouill, S., Podar, K., Amiot, M., Hideshima, T., Chauhan, D., Ishitsuka, K., Kumar, S., Raje, N., Richardson, P. G., Harousseau, J. L., Anderson, K. C. (2004) VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis. Blood 104, 2886-2892.
37. Hideshima, T., Mitsiades, A., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N. C., Mitsiades, N., Anderson, K. C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101, 1530-1534.
38. Boccadoro, M., Morgan, G., Cavenagh, J. (2005) Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 5, 18-26.
39. Podar, K., Shringarpure, R., Tai, Y. T., Simoncini, M., Sattler, M., Ishitsuka, K., Richardson, P. G., Hideshima, T., Chauhan, D., Anderson, K. C. (2004) Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 64, 7500-7506.
40. Wohlbold, L., Van Der Kuip, H., Miething, C., Vornlocher, H. P., Knabbe, C., Duyster, J., Aulitzky, W. E. (2003) Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (ST571). Blood 102, 2236-2239.
41. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., Kabbinavar, F. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342.
42. Santos, S. C., Dias, S. (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103, 3883-3889.
43. Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., Iruela-Arispe, M. L. (2007) Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
44. Podar, K., Anderson, K. C. (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105, 1383-1395.
45. Hideshima, T., Chauhan, D., Richardson, P., Anderson, K. C. (2005) Identification and validation of novel therapeutic targets for multiple myeloma. J. Clin. Oncol. 23, 6345-6350.
46. Mitsiades, C. S., Mitsiades, N. S., Munshi, N. C., Richardson, P. G., Anderson, K. C. (2006) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer 42, 1564-1573.
47. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J., Anderson, K. C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-3076.
48. Rose-John, S., Waetzig, G. H., Scheller, J., Grötzinger, J., Seegert, D. (2007) The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets 11, 613-624.
49. Chalaris, A., Rabe, B., Paliga, K., Lange, H., Laskay, T., Fielding, C. A., Jones, S. A., Rose-John, S., Scheller, J. (2007) Apoptosis is a natural stimulus of IL6R shedding and contributes to the pro-inflammatory trans-signaling function of neutrophils. Blood 110, 1748-1755.
50. Kallen, K-J. (2002) The role of transsignaling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592, 323-343.
51. Kumar, V., Varma, N., Varma, S., Vohra, H., Malhotra, P., Dutta, U., Sharma, S. C. (2004) Flow cytometric analysis of DNA indices, expression of p53 and multidrug resistance genes in multiple myeloma patients. Anal. Quant. Cytol. Histol. 26, 271-277.
52. Schwarzenbach, H. (2002) Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med. Oncol. 19, 87-104.
53. Sonneveld, P. (2000) Multidrug resistance in haematological malignancies. J. Intern. Med. 247, 521-534.
54. Rumpold, H., Salvador, C., Wolf, A. M., Tilg, H., Gastl, G., Wolf, D. (2007) Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem. Biophys. Res. Commun. 361, 549-554.
55. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-genthe, C., Gottesman, M. M. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234.